Stock market historians may dub 2017 the Xanax year. Traditional historians will probably choose a different moniker.

Stock markets in many advanced economies have been unusually calm during 2017, reported Schwab’s Jeffrey Kleintop in a May 15, 2017 commentary. The CBOE Volatility Index, a.k.a. the Fear Gauge, which measures how volatile investors believe the S&P 500 Index will be over the next few months, has fallen below 10 on just 15 days since the index was introduced in 1990. Six of the 15 occurred during 2017. The average daily closing value for the VIX was 19.7 from 1990 through 2016. For 2017, the average has been 11.8.

Investors’ calm is remarkable because 2017 has not been a particularly calm year. We’ve experienced significant geopolitical events. For example, the U.S. launched a military strike on Syria, and dropped its biggest non-nuclear bomb on Afghanistan. There have been terrorist attacks in Europe, along with discord in the Middle East. The European Union has been unraveling. The U.S. government has shown unusual levels of disarray, and the U.S. President’s passion for Tweets has stirred the pot.

Just last week, the future of Brexit was thrown into question when Britain’s snap elections produced a hung Parliament (no political party has a majority). How did investors react? Barron’s reported the European markets shrugged off Thursday’s election results and moved higher on Friday, offsetting some losses from earlier in the week.

In the United States, Former FBI Director James Comey’s testimony didn’t have much effect on stock markets last week, according to Barron’s. However, comments from Goldman Sachs cautioned the trade in big technology stocks, which have accounted for about 40 percent of the Standard & Poor’s 500 Index’s gains this year, was too crowded. The ensuing clamor resulted in the NASDAQ losing 1.6 percent for the week and the S&P 500 finishing slightly lower.

Geopolitical events do not appear to have the impact they may once have had. The Fear Gauge finished Friday at 10.7.

table-6-13-17

Guess What? The Fountain Of Youth Isn’t Really A Fountain

For millennia, humankind has been looking for a means of slowing aging, maintaining health, and restoring youth and beauty. Greek mythology tells us that Hebe, the daughter of Zeus and Hera, could restore youth. In the 1600s, Juan Ponce de Leon was rumored to have searched Florida for the Fountain of Youth. In modern times, many people have turned to their surgeons and dermatologists with varied results.

The latest news in the search for youth and vitality involves metabolites. In 2013, a paper published by Harvard’s David Sinclair, along with other researchers, suggested it might be possible to reverse mitochondrial decay, which is thought to be a key driver of aging, by consuming nicotinamide riboside (NR) supplements, reported Scientific American. A 2015 guest blog post opined:

“If I were a middle-aged mouse, I’d be ready to spend some of the nickels and dimes I’d dragged off the sidewalk to try NR supplements. Even before Sinclair’s paper, researchers had shown in 2012 that when given doses of NR, mice on high-fat diets gained 60 percent less weight than they did on the same diets without NR. Further, none of the mice on NR showed signs of diabetes, and their energy levels improved.”

In March of this year, Science published a paper that expands on prior findings. The research suggests it may be possible to help cells repair damaged DNA by restoring levels of an oxidized form of nicotinamide adenine dinucleotide (NAD).

NASA is supporting the work, according to ScienceDaily. If supplements prove effective with humans, it might help keep astronauts – who “experience accelerated ageing from cosmic radiation, suffering from muscle weakness, memory loss and other symptoms when they return” – healthy during a four-year mission to Mars.